Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 20, 2026 08:55 ET | Source: Foresight Autonomous Holdings Ltd.

Foresight: Eye-Net and SoftBank Corp. Advance Strategic Collaboration in Japan

Parties are collaborating in a multi-phase plan to assess Eye-Net’s collision prevention V2X technology to protect both vehicles and vulnerable road users Ness Ziona, Israel, Jan. 20, 2026 (GLOBE...
January 20, 2026 07:07 ET | Source: Gilat Satellite Networks Ltd.

Gilat Receives Approximately $11 Million SkyEdge Platform Order from Leading Satellite Operator in Asia Pacific

PETAH TIKVA, Israel, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Gilat Satellite Networks Ltd. (NASDAQ: GILT, TASE: GILT), a worldwide leader in satellite networking technology, solutions, and services, today...
January 20, 2026 07:00 ET | Source: Can-Fite BioPharma Ltd.

Can-Fite Completes Patient Enrollment in Phase 2a Pancreatic Cancer Study of Namodenoson

Primary Safety Endpoint Demonstrated to Date; Top-Line Efficacy Data Expected in Q3 2026 Ramat Gan, Israel, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:...
January 20, 2026 06:00 ET | Source: Tower Semiconductor

Tower Semiconductor Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Conference Call

MIGDAL HAEMEK, Israel – January 20, 2026 – Tower Semiconductor (NASDAQ/ TASE: TSEM), the leading foundry of high value analog semiconductor solutions, will issue its fourth quarter and fiscal year...
January 15, 2026 11:25 ET | Source: UMH Properties, Inc.

UMH PROPERTIES, INC. WILL HOST FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS WEBCAST AND CONFERENCE CALL

FREEHOLD, NJ, Jan. 15, 2026 (GLOBE NEWSWIRE) -- UMH Properties, Inc. (NYSE: UMH) (TASE: UMH), a real estate investment trust (REIT) specializing in manufactured home communities, announced that it...
January 14, 2026 17:02 ET | Source: Teva Pharmaceutical Industries Ltd

AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicine

AJOVY demonstrated efficacy and a consistent safety profile in the SPACE trial, making it the first and only calcitonin gene-related peptide (CGRP) antagonist treatment option for both pediatric and...
January 13, 2026 09:28 ET | Source: XTL Biopharmaceuticals Ltd.

XTL Biopharmaceuticals Acquires 85% of NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership

Unmatched scientific firepower: Two Nobel Laureates join Founder Prof. Haitham Amal, leading global autism researcher Critical unmet need: 1 in 31 U.S. children now affected, zero FDA-approved...
January 12, 2026 07:30 ET | Source: BrainsWay

BrainsWay Announces FDA Approval of Neurolief’s Proliv™Rx Neuromodulation System for Major Depressive Disorder (MDD)

BURLINGTON, Mass. and JERUSALEM, Jan. 12, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation...
January 11, 2026 18:00 ET | Source: Teva Pharmaceutical Industries Ltd

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation

TEL AVIV, Israel, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) will present its ongoing transformation and expected growth trajectory through 2030 at...
January 11, 2026 17:00 ET | Source: Teva Pharmaceutical Industries Ltd

Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million to support Teva’s anti-IL-15 candidate...